❌

Normal view

Think Before You Drive: World Model-Inspired Multimodal Grounding for Autonomous Vehicles

arXiv:2512.03454v3 Announce Type: replace-cross Abstract: Interpreting natural-language commands to localize target objects is critical for autonomous driving (AD). Existing visual grounding (VG) methods for autonomous vehicles (AVs) typically struggle with ambiguous, context-dependent instructions, as they lack reasoning over 3D spatial relations and anticipated scene evolution. Grounded in the principles of world models, we propose ThinkDeeper, a framework that reasons about future spatial states before making grounding decisions. At its core is a Spatial-Aware World Model (SA-WM) that learns to reason ahead by distilling the current scene into a command-aware latent state and rolling out a sequence of future latent states, providing forward-looking cues for disambiguation. Complementing this, a hypergraph-guided decoder then hierarchically fuses these states with the multimodal input, capturing higher-order spatial dependencies for robust localization. In addition, we present DrivePilot, a multi-source VG dataset in AD, featuring semantic annotations generated by a Retrieval-Augmented Generation (RAG) and Chain-of-Thought (CoT)-prompted LLM pipeline. Extensive evaluations on six benchmarks, ThinkDeeper ranks #1 on the Talk2Car leaderboard and surpasses state-of-the-art baselines on DrivePilot, MoCAD, and RefCOCO/+/g benchmarks. Notably, it shows strong robustness and efficiency in challenging scenes (long-text, multi-agent, ambiguity) and retains superior performance even when trained on 50% of the data.

Low-dose intestinal irradiation enhances the efficacy and prognosis of PD-1 blockade in metastatic non-small cell lung cancer

Clin Cancer Res. 2026 Mar 18. doi: 10.1158/1078-0432.CCR-25-4153. Online ahead of print.

ABSTRACT

PURPOSE: Intestinal low-dose irradiation (ILDR) may enhance immunotherapy efficacy by modulating the gut microbiota and metabolism; however, its role in metastatic non-small cell lung cancer (mNSCLC), particularly in the first-line setting, remains unclear.

EXPERIMENTAL DESIGN: This multicenter retrospective and prospective study included mNSCLC patients receiving first- and second-line programmed cell death protein 1 (PD-1) inhibitors along with abdominopelvic radiotherapy between 2018 and 2025. Patients were stratified by the mean intestinal radiation dose into <1 Gy, 1-3 Gy, and >3 Gy groups and treatment outcomes were compared. The blood and fecal samples were subjected to multi-omics profiling.

RESULTS: g>309 patients were included in the retrospective analysis. Optimal efficacy was observed with a small intestinal mean radiation dose (SIMRD) of 1-3 Gy, showing longer progression-free survival (PFS, 10.2 months) and overall survival (OS, 22.8 months) (P < 0.01), which was consistent across subgroups. Compared with 1-3 Gy, SIMRD >3 Gy (Hazard ratio [HR] = 4.87, P < 0.001) and <1 Gy (HR = 1.85, P < 0.001) independently predicted worse OS. Prospective results confirmed the best disease control rate (P = 0.041) and PFS (P = 0.046) with SIMRD of 1-3 Gy. Responders were enriched in Bacillota, Clostridia, and indole derivatives, particularly indole-3-carboxylic acid. Moreover, the 1-3 Gy group exhibited increased circulating macrophage inflammatory protein-3α and reduced circulating α4β7+ regulatory T cells.

CONCLUSIONS: ILDR influences the efficacy of PD-1 blockade in patients with mNSCLC, particularly when SIMRD is maintained within the 1-3 Gy range, likely through modulation of the gut microbiota-metabolite-immune axis.

PMID:41849236 | DOI:10.1158/1078-0432.CCR-25-4153

❌